gardiquimod TFA salt

Name: gardiquimod TFA salt
Brand: TargetMol
SKU: T5499
Rating: 4.5 (1 reviews)

还可以

产品编号 T5499Cas号 1159840-61-5

Gardiquimod diTFA，咪唑啉类似物TLR7/8激动剂，可特异性抑制巨噬细胞和活化外周血单个核细胞(PBMCs)的HIV-1感染。在浓度低于10 μM时，该化合物特异性激活TLR7。

还可以

产品编号 T5499Cas号 1159840-61-5

规格	价格	库存	数量
2 mg	¥ 326	5日内发货
5 mg	¥ 523	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

联系我们获取更多批次信息

资源下载

产品介绍

生物活性

产品描述	Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM. Gardiquimod diTFA could function as both an immune system modifier and a reverse transcriptase inhibitor as a novel therapeutic agent to block systemic and mucosal transmission of HIV-1.[1] [2].
体外活性	Gardiquimod diTFA (6-60 μM ) significantly inhibits HIV-1 reverse transcriptase to synthesis of cDNA [1].
体内活性	Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) enhances the anti-tumor effects of NK cells [2]. Animal Model: Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts) [2] Dosage: 1 mg/kg per mouse Administration: i.p.; daily for 7 days Result: Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.